::: 台灣東洋製藥 | TTY Biopharm :::

Research and Development

Core technologies

Core technologies – liposomal formulations, microemulsion formulations, sustained-release oral formulations, sustained-release injection formulations, and new drug development. With the improvement of dosage forms, we provide the public with a better quality of life and medical care. TTY Biopharm is dedicated to extended research and commercialization of new drugs to lead Taiwan to a new territory of Western pharmaceutical technology.

Liposome - Nanotechnology

Successfully acquire the first liposomal drug approval for Lipo-Dox in 1998.
Acquire the approval for launch of Doxorubicin, the first liposomal formulation in Taiwan and the third in the world.
Acquire subsidies from Industrial Technology Development Program for subsequent R&D projects.

Sustained-release formulation – controlled-release technology

Successfully acquired the new drug approval for the sustained-release formulation Regrow, launched in 1998, to overcome the disadvantage of frequent medication in-takes for short-acting drugs and improve the patient's cooperation in and the safety of taking medications.
A sustained-release mucolytic drug and an antipyretic analgesic have entered the clinical trial stage.
The continual development of sustained-release drugs includes high-dosage, low-solubility pharmaceutical products.

New drug development – new indications and formulations

TTY Biopharm has devoted much effort to clinical trials since its establishment in 1996 and more than 100 clinical trials have been completed or are in progress to acquire many new indications.